Cofoe Medical Technology (301087) Q4 2024 earnings summary

Executive summary

• Revenue rose 4.53% YoY to RMB2.983bn; attributable net income increased 22.60% to RMB311.8m and adjusted net income grew 36.74% to RMB275.1m.

• Cash generation strengthened: operating cash flow advanced 68.45% to RMB663.4m, while management cited stronger collections and lower payments for materials and goods.

• Results reflected sharply higher rehabilitation-aid and medical-care sales, offset by declines in health-monitoring and respiratory-support products; higher selling costs pressured profitability in some newer businesses.

Financial highlights

• FY24 revenue was RMB2.983bn, up 4.53% YoY; healthcare products contributed RMB2.842bn, up 5.02%, while other revenue fell 4.49%.

• Attributable net income was RMB311.8m, up 22.60%; excluding non-recurring gains, attributable net income was RMB275.1m, up 36.74%.

• Consolidated net income reached RMB312.3m versus RMB252.9m; operating profit rose to RMB373.3m from RMB294.7m.

• Sales expenses increased 31.40% to RMB973.3m, reflecting hearing-center expansion and higher e-commerce service, promotion and brand-building costs.

• Quarterly revenue was RMB807.2m, RMB751.5m, RMB690.0m and RMB734.3m from Q1 to Q4; attributable net income was RMB101.2m, RMB83.8m, RMB66.9m and RMB59.8m, respectively.

Outlook and guidance

• 2025 priorities include core-product R&D, AI-enabled home-health devices, smart manufacturing, value-chain cost control, channel productivity and overseas expansion; no numeric revenue or earnings target is specified.

• Planned launches span health monitoring, rehabilitation aids, respiratory support, medical care and traditional-therapy products; respiratory plans include upgrading the connected-care platform with real-time waveform analysis and tiered alerts.

• Hearing operations will prioritize store efficiency, expense control, customer conversion and a more selective expansion pace to improve profitability while balancing growth and returns.